AASLD 2015

AASLD 2015

Antivirals Benefit Hep B Patients With Normal or Elevated ALT

Antiviral therapy in patients with non-cirrhotic chronic hepatitis B (CHB) and normal to minimally-elevated alanine aminotransferase (ALT) levels significantly reduced the risk of hepatocellular carcinoma, reported Joseph K. Hoang from Stanford University Medical Center, Palo Alto, CA, at The Liver Meeting® 2015.

Once-Daily Dual DAA Combo: 97% SVR12 in HCV GT1

The combination of two next-generation direct-acting antiviral (DAA) agents, ABT-493 and ABT-530, was “well tolerated,” with all non-cirrhotic patients with hepatitis C virus (HCV) genotype 1 (GT1) infection who completed the 8-week treatment period achieving sustained virologic response at 12 weeks (SVR12), a study presented at The Liver Meeting 2015® has found.